Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial | Zendy

Kaini Shen | Zendy; Weijun Fu | Zendy; Yu Wu | Zendy; Yujun Dong | Zendy; Zhongxia Huang | Zendy; Yongqiang Wei | Zendy; Chunrui Li | Zendy; Chunyan Sun | Zendy; Ye Chen | Zendy; Huilei Miao | Zendy; Yuelun Zhang | Zendy; Xinxin Cao | Zendy; Daobin Zhou | Zendy; Li J | Zendy

Open Access

Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial

Author(s) -

Kaini Shen,

Weijun Fu,

Yu Wu,

Yujun Dong,

Zhongxia Huang,

Yongqiang Wei,

Chunrui Li,

Chunyan Sun,

Ye Chen,

Huilei Miao,

Yuelun Zhang,

Xinxin Cao,

Daobin Zhou,

Li J

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.121.055953

Subject(s) - medicine , bortezomib , al amyloidosis , doxycycline , dexamethasone , randomized controlled trial , cyclophosphamide , amyloidosis , chemotherapy , oncology , immunoglobulin light chain , multiple myeloma , immunology , antibiotics , antibody , biology , microbiology and biotechnology

Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain amyloidosis. Therefore, we prospectively compared the efficacy of bortezomib-cyclophosphamide-dexamethasone (CyBorD) and CyBorD combined with doxycycline for cardiac light chain amyloidosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research